Results 161 to 170 of about 15,565,904 (256)

Integrated Virtual Screening and Molecular Electrostatic Surface Potential Descriptors for Predicting BACE1 Inhibitor Interactions in Alzheimer's Disease. [PDF]

ACS Omega
Alvarez-Ginarte Y, López R, García de la Vega JM, De Ema I, Alpízar-Pedraza D.   +4 more
europepmc   +1 more source

Body Surface Potential Mapping: Contemporary Applications and Future Perspectives. [PDF]

Hearts (Basel), 2021
Bergquist J, Rupp L, Zenger B, Brundage J, Busatto A, MacLeod RS.   +5 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Body surface potential mapping of the cortico-muscular axis using smart textile electrode arrays. [PDF]

Nat Commun
Serrano RR, Brunt C, Tao X, Zajaczkowski M, Dominguez-Alfaro A, Picchio ML, Mantione D, Drakakis EM, Mecerreyes D, Malliaras GG.   +9 more
europepmc   +1 more source

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework. [PDF]

MAbs, 2023
Ollier R, Fuchs A, Gauye F, Piorkowska K, Menant S, Ratnam M, Montanari P, Guilhot F, Phillipe D, Audrain M, Egesipe AL, Névoltris D, Seredenina T, Pfeifer A, Kosco-Vilbois M, Afroz T.   +15 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Moisture-induced autonomous surface potential oscillations for energy harvesting. [PDF]

Nat Commun, 2021
Long Y, He P, Shao Z, Li Z, Kim H, Yao AM, Peng Y, Xu R, Ahn CH, Lee SW, Zhong J, Lin L.   +11 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Molecular Electrostatic Surface Potential: A Predictive Framework for Noncovalent Interactions and Adsorption Characteristics in Molecular Entities. [PDF]

Int J Mol Sci
Varadwaj PR, Marques HM, Varadwaj A, Grabowski I, Yamashita K.   +4 more
europepmc   +1 more source

Surface Potential Driven Water Harvesting from Fog. [PDF]

ACS Nano, 2021
Ura DP, Knapczyk-Korczak J, Szewczyk PK, Sroczyk EA, Busolo T, Marzec MM, Bernasik A, Kar-Narayan S, Stachewicz U.   +8 more
europepmc   +1 more source